Substance Abuse Treatment in Persons with HIV/AIDS: Challenges in Managing Triple Diagnosis

REFERENCES

• Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatr. 2001;58(8):721.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS. 2004;18:43–48.
   PubMed Web of Science ®Google Scholar
• Masson C, Sorensen J, Phibbs C, Okin R. Predictors of medical service utilization among individuals with co-occurring HIV infection and substance abuse disorders. AIDS Care. 2004;16(6):744–755.
   PubMed Web of Science ®Google Scholar
• Conigliaro J, Madenwald T, Bryant K, et al. The veterans aging cohort study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. Alcoholism: Clin Exp Res. 2004;28(2):313–321.
   PubMed Web of Science ®Google Scholar
• Kelley JL, Petry NM. HIV risk behaviors in male substance abusers with and without antisocial personality disorder. J Subst Abuse Treat. 2000;19(1):59–66.
   PubMed Web of Science ®Google Scholar
• Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients. Drugs. 2006;66(6):769–789.
   PubMed Web of Science ®Google Scholar
• Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–387.
   PubMed Web of Science ®Google Scholar
• Klinkenberg W, Sacks S, for the Hiv/aids Treatment Adherence, Health Outcomes and Cost Study Group: mental disorders and drug abuse in persons living with HIV/AIDS. AIDS Care. 2004;16(sup1):22–42.
   Web of Science ®Google Scholar
• Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission. J Homosex. 2001;41(2):17–35.
   PubMed Web of Science ®Google Scholar
• Goldstein RB, Rotheram-Borus MJ, Johnson MO, et al. Insurance coverage, usual source of care, and receipt of clinically indicated care for comorbid conditions among adults living with human immunodeficiency virus. Med Care. 2005;43(4):401–410.
   PubMed Web of Science ®Google Scholar
• Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatr. 2001;58(8):729.
   PubMed Web of Science ®Google Scholar
• Zaller N, Gillani F, Rich J. A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care. 2007;19(9):1128–1133.
   PubMed Web of Science ®Google Scholar
• Douaihy A, Daley D, Stowell K, Park T. Relapse prevention: clinical strategies for substance use disorders. In: Witkiewitz K, Marlatt GA, ed. Therapist's Guide to Evidence-based Relapse Prevention. Burlington, MA : Academic Press; 2007:37–73.
   Google Scholar
• Gupta M, Kumar K, Garg P. Dual diagnosis vs. triple diagnosis in HIV: A comparative study to evaluate the differences in psychopathology and suicidal risk in HIV positive male subjects. Asian J Psychiatr. 2013.
   Google Scholar
• Buseh AG, Stevens PE, McManus P, Addison RJ, Morgan S, Millon-Underwood S. Challenges and opportunities for HIV prevention and care: insights from focus groups of HIV-infected African American men. JANAC. 2006;17(4):3–15.
   Google Scholar
• Brown Jr LS, Kritz SA, Goldsmith RJ, et al. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the national drug abuse treatment clinical trials network. J Subst Abuse Treat. 2006;30(4):315–321.
   PubMed Web of Science ®Google Scholar
• Uldall K, Palmer N, Whetten K, Mellins C. HIV/AIDS treatment adherence, health outcomes and cost study group. Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. AIDS Care. 2004;16(1):S71–S96.
   Google Scholar
• Francis H. Substance abuse and HIV infection. Top HIV Med. 2003;11(1):20–24.
   PubMedGoogle Scholar
• Galvan FH, Burnam MA, Bing EG. Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people. J Psychoactive Drugs. 2003;35(sup1):153–160.
   PubMed Web of Science ®Google Scholar
• Carrico AW, Johnson MO, Moskowitz JT, et al. Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy. Psychosom Med. 2007;69(8):785–792.
   PubMed Web of Science ®Google Scholar
• Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. JAIDS. 2005;38(1):96–103.
   Google Scholar
• Raboud JM, Abdurrahman ZB, Major C, et al. Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. JAIDS. 2005;39(3):327–332.
   Google Scholar
• Scott JD, Wald A, Kitahata M, et al. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS. 2009;23(11):925–929.
   PubMed Web of Science ®Google Scholar
• Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21):948–952.
   PubMed Web of Science ®Google Scholar
• Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–193.
   PubMed Web of Science ®Google Scholar
• Grierson J, Koelmeyer R, Smith A, Pitts M. Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med. 2011;12(9):562–569.
   PubMed Web of Science ®Google Scholar
• Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108.
   PubMed Web of Science ®Google Scholar
• Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–194.
   PubMed Web of Science ®Google Scholar
• Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99(3):361–368.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21(8):564–574.
   PubMed Web of Science ®Google Scholar
• Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–739.
   PubMed Web of Science ®Google Scholar
• Colfax G. The methamphetamine epidemic: implications for HIV prevention and treatment. Current HIV/AIDS Reports. 2005;2(4):194–199.
   PubMedGoogle Scholar
• Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis. 2005;24(3):115–132.
   PubMed Web of Science ®Google Scholar
• Halkitis PN. Reframing HIV prevention for gay men in the united states. Am Psychol. 2010;65(8):752.
   PubMed Web of Science ®Google Scholar
• Barroso J, Sandelowski M. Substance abuse in HIV-positive women. JANAC. 2004;15(5):48–59.
   Google Scholar
• Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev. 2005;25(4):433–457.
   PubMed Web of Science ®Google Scholar
• Pollack HA, D’Aunno T, Lamar B. Outpatient substance abuse treatment and HIV prevention: an update. J Subst Abuse Treat. 2006;30(1):39–47.
   PubMed Web of Science ®Google Scholar
• Orwat J, Saitz R, Tompkins CP, Cheng DM, Dentato MP, Samet JH. Substance abuse treatment utilization among adults living with HIV/AIDS and alcohol or drug problems. J Subst Abuse Treat. 2011;41(3):233–242.
   PubMed Web of Science ®Google Scholar
• Lundgren LM, Delgado M. HIV outreach and substance abuse treatment for Latino drug users: implications for program planning. Eval Program Plan. 2008;31(1):61–63.
   PubMed Web of Science ®Google Scholar
• Korthuis PT, Josephs JS, Fleishman JA, et al. Substance abuse treatment in human immunodeficiency virus: the role of patient–provider discussions. J Subst Abuse Treat. 2008;35(3):294–303.
   PubMed Web of Science ®Google Scholar
• Rubenstein D, Sorrentino D. Psychotherapy with HIV/AIDS patients: assessment and treatment plan development. Am J Psychother. 2008;62(4):365–375.
   PubMedGoogle Scholar
• Dausey DJ, Desai RA. Psychiatric comorbidity and the prevalence of HIV infection in a sample of patients in treatment for substance abuse. J Nerv Ment Dis. 2003;191(1):10–17.
   PubMed Web of Science ®Google Scholar
• Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatr. 2001;158(5):725–730.
   PubMed Web of Science ®Google Scholar
• Parsons JT, Rosof E, Mustanski B. Patient-related factors predicting HIV medication adherence among men and women with alcohol problems. J Health Psychol. 2007;12(2):357–370.
   PubMed Web of Science ®Google Scholar
• Hosek SG, Harper GW, Domanico R. Predictors of medication adherence among HIV-infected youth. Psychol, Health Med. 2005;10(2):166–179.
   PubMedGoogle Scholar
• Farley M, Golding JM, Young G, Mulligan M, Minkoff JR. Trauma history and relapse probability among patients seeking substance abuse treatment. J Subst Abuse Treat. 2004;27(2):161–167.
   PubMed Web of Science ®Google Scholar
• Martin L, Kagee A. Lifetime and HIV-related PTSD among persons recently diagnosed with HIV. AIDS Behav. 2011;15(1):125–131.
   PubMed Web of Science ®Google Scholar
• Machtinger E, Wilson T, Haberer J, Weiss D. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091–2100.
   PubMed Web of Science ®Google Scholar
• Hansen NB, Cavanaugh CE, Vaughan EL, Connell CM, Tate DC, Sikkema KJ. The influence of personality disorder indication, social support, and grief on alcohol and cocaine use among HIV-positive adults coping with AIDS-related bereavement. AIDS Behav. 2009;13(2):375–384.
   PubMed Web of Science ®Google Scholar
• Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009;32(5):389–405.
   PubMed Web of Science ®Google Scholar
• Johnson JG, Williams JB, Goetz RR, et al. Personality disorders predict onset of axis I disorders and impaired functioning among homosexual men with and at risk of HIV infection. Arch Gen Psychiatr. 1996;53(4):350–357.
   PubMedGoogle Scholar
• Perkins DO, Davidson EJ, Leserman J, Liao D. Personality disorder in patients infected with HIV: a controlled study with implications for clinical care. Am J Psychiatr. 1993.
   PubMed Web of Science ®Google Scholar
• Jacobsberg L, Frances A, Perry S. Axis II diagnoses among volunteers for HIV testing and counseling. Am J Psychiatr. 1995;152(8):1222–1224.
   PubMed Web of Science ®Google Scholar
• James ME, Rubin CP, Willis SE. Drug abuse and psychiatric findings in HIV-seropositive pregnant patients. Gen Hosp Psychiatr. 1991;13(1):4–8.
   PubMed Web of Science ®Google Scholar
• Golding M, Perkins DO. Personality disorder in HIV infection. Int Rev Psychiatr. 1996;8(2–3):253–258.
   Web of Science ®Google Scholar
• Newville H, Haller DL. Relationship of axis II pathology to sex-and drug-related risk behaviors among patients in HIV primary care. AIDS Care. 2012;24(6):763–768.
   PubMed Web of Science ®Google Scholar
• Welch S. Substance use and personality disorders. Psychiatry. 2007;6(1):27–29.
   Google Scholar
• Martin AM, Benotsch EG, Perschbacher LanceS, Green M. Transmission risk behaviors in a subset of HIV-positive individuals: the role of narcissistic personality features. Pers Ind Diff. 2012.
   Web of Science ®Google Scholar
• Wagner EE, Miller AL, Greene LI, Winiarski MG. Dialectical behavior therapy for substance abusers adapted for persons living with HIV/AIDS with substance use diagnoses and borderline personality disorder. Cogn Behav Pract. 2004;11(2):202–212.
   Web of Science ®Google Scholar
• Halkitis PN, Wolitski RJ, Millett GA. A holistic approach to addressing HIV infection disparities in gay, bisexual, and other men who have sex with men. Am Psychol. 2013;68(4):261–273.
   PubMed Web of Science ®Google Scholar
• Ferrando SJ. Features-substance abuse and HIV infection-this article reviews substance use, comorbid psychiatric disorders, and risk behaviors for HIV; the prevalence of substance use disorders among. Psychiatr Ann. 2001;31(1):57–62.
   Google Scholar
• Timko C, Dixon K, Moos RH. Treatment for dual diagnosis patients in the psychiatric and substance abuse systems. Ment Health Serv Res. 2005;7(4):229–242.
   PubMedGoogle Scholar
• Ferrando SJ, Batki SL. Substance abuse and HIV infection. New Dir Ment Health Serv. 2000;(87):57–67.
   PubMedGoogle Scholar
• Margolin A, Avants SK, DePhilippis D, Kosten TR. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am J Drug Alcohol Abuse. 1998;24(1):85–101.
   PubMed Web of Science ®Google Scholar
• Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113(2):192–199.
   PubMed Web of Science ®Google Scholar
• Esposito-Smythers C, Brown LK, Wolff J, et al. Substance abuse treatment for HIV infected young people: an open pilot trial. J Subst Abuse Treat. 2013.
   PubMedGoogle Scholar
• Daughters SB, Magidson JF, Schuster RM, Safren SA. ACT HEALTHY: A combined cognitive-behavioral depression and medication adherence treatment for HIV-infected substance users. Cogn Behav Pract. 2010;17(3):309–321.
   PubMedGoogle Scholar
• Shoptaw S, Reback CJ, Larkins S, et al. Outcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men. J Subst Abuse Treat. 2008;35(3):285–293.
   PubMed Web of Science ®Google Scholar
• Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. JAIDS. 2001;27(3):251–259.
   Google Scholar
• Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med. 2003;4(1):33–37.
   PubMedGoogle Scholar
• Prochaska JO, DiClemente CC. The transtheoretical approach. In: Norcross JC, Goldfried MR, eds. Handbook of Psychotherapy Integration. Vol. 2. New York, NY : Oxford University Press; 1992:147–171.
   Google Scholar
• Bouis S, Reif S, Whetten K, Scovil J, Murray A, Swartz M. An integrated, multidimensional treatment model for individuals living with HIV, mental illness, and substance abuse. Health Soc Work. 2007;32(4):268–278.
   PubMed Web of Science ®Google Scholar
• Dunn C, Deroo L, Rivara FP. The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. Addiction. 2001;96(12):1725–1742.
   PubMed Web of Science ®Google Scholar
• Parsons JT, Rosof E, Punzalan JC, Maria LD. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care & STDs. 2005;19(1):31–39.
   PubMed Web of Science ®Google Scholar
• Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV crack cocaine users. Drug Alcohol Depend. 2011;116(1):177–187.
   PubMed Web of Science ®Google Scholar
• Feaster DJ, Mitrani VB, Burns MJ, et al. A randomized controlled trial of structural ecosystems therapy for HIV medication adherence and substance abuse relapse prevention. Drug Alcohol Depend. 2010;111(3):227–234.
   PubMed Web of Science ®Google Scholar
• Granholm E, Anthenelli R, Monteiro R, Sevcik J, Stoler M. Brief integrated outpatient dual diagnosis treatment reduces psychiatric hospitalizations. Am J Addict. 2003;12(4):306–313.
   PubMed Web of Science ®Google Scholar
• Markowitz JC, Spielman LA, Sullivan M, Fishman B. An exploratory study of ethnicity and psychotherapy outcome among HIV-positive patients with depressive symptoms. J Psychother Pract Res. 2000;9(4):226.
   PubMedGoogle Scholar
• Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–366.
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet.2013.
   Web of Science ®Google Scholar